# Understanding the Shandra Eisenga Human Cell and Tissue Product Safety Act

This bill is about making sure people know the real risks involved when they receive transplants made from human cells and tissues. These products are used in many medical procedures—things like skin grafts for burn victims, bone grafts for orthopedic surgery, and various tissue replacements. The bill requires the federal government to launch a public education campaign to tell both patients and doctors about the potential dangers, particularly the risk of getting serious infections like tuberculosis or sepsis from these transplants. Right now, many people don't realize these products can carry infection risks, so the government would work with nonprofits to spread this information through TV, radio, social media, and other channels.

The bill also strengthens enforcement against companies that don't follow safety rules. If a company that manufactures these cell and tissue products violates federal regulations, they can now face significant financial penalties—up to $20,000 per violation or per day of ongoing violations, plus they'd have to pay back the retail value of the products involved. There's a cap of $10 million in penalties per case, but this is still a serious consequence designed to make companies take safety seriously.

Additionally, the bill requires the Food and Drug Administration to take a hard look at how well they're currently overseeing these manufacturers. Within two years, they must report to Congress about how often they're inspecting these facilities, whether they're doing enough screening of donors, and what new rules might be needed. The FDA also has to review and update its guidelines for determining which donors are safe to use for these products, making sure the standards are current and protective.

Shandra Eisenga Human Cell and Tissue Product Safety Act

Moolenaar, John R.

Shandra Eisenga Human Cell and Tissue Product Safety ActThis bill requires the Department of Health and Human Services (HHS) to educate the public and health care providers about the benefits and risks of transplants that use human cell or tissue products, including the risk of infections.HHS must develop the educational campaign after taking into consideration information about products that carry the highest risk of transmitting infections to transplant recipients. HHS may award grants to other entities to conduct public awareness initiatives and media campaigns about the risk of infections.&nbsp;The bill also establishes specific civil penalties for violations of laws regarding the spread of communicable diseases and regulations regarding procedures for human cell or tissue products.